ESR1 and breast cancer: Shaitelman et al. [24] conducted a study of statin use among triple-negative (ER-negative, PR-negative, HER2-negative) breast cancer and found no significant association between statin use and overall survival (HR 0.74, 95% CI 0.20–2.77).